Drug intelligence / Profile preview

enteropathogenic Escherichia coli

Development stage
Discontinued
Lead developer
Stanford University
Administration
Oral
01

Overview

Enteropathogenic Escherichia coli (EPEC) is a significant human bacterial pathogen and a leading cause of infantile diarrhea, particularly in developing regions. In the context of clinical research, EPEC is utilized as a challenge agent in controlled human infection models (CHIMs) to study the pathophysiology of bacterial diarrhea and to evaluate the protective effects of various factors, such as gastric acidity or pre-existing infections like Helicobacter pylori. The pathogen's virulence is primarily mediated by a Type III secretion system (T3SS) encoded by the Locus of Enterocyte Effacement (LEE) pathogenicity island. This system allows the bacteria to inject effector proteins directly into host enterocytes, leading to the formation of attaching and effacing (A/E) lesions, cytoskeletal rearrangement, and the development of actin-rich pedestal structures that facilitate bacterial colonization and disrupt intestinal absorption.

Other names
EPECenteropathogenic E. coli

Beyond the preview

Go deeper on enteropathogenic Escherichia coli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on enteropathogenic Escherichia coli.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call